Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: A characterization with α/β- adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors

International Journal of Neuropsychopharmacology

Volumn 10, Issue 5, 2007, Pages 579-593

  Millan, Mark J ^a   Dekeyne, Anne ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antidepressant; Corticotrophin releasing factor (CRF); Melanin concentrating hormone (MCH); Neurokinin 1 (NK1); Norepinephrine transporter

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ATIPAMEZOLE; BETA ADRENERGIC RECEPTOR; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; IDAZOXAN; IMIPRAMINE; MANIFAXINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NEUROPEPTIDE RECEPTOR; NISOXETINE; NOMIFENSINE; PAROXETINE; PRAZOSIN; REBOXETINE; S 33005; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; TRANQUILIZING ACTIVITY;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; MALE; MORPHOLINES; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE; SEROTONIN UPTAKE INHIBITORS;

EID: 34948822243     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706007309     Document Type: Article

References (89)

1. Arnt J (1992). Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats. Behavioural Pharmacology 3, 11-18.
2. 2C) adrenoceptors. Cellular Signalling 14, 829-837.
3. 1A activity in the discriminative stimulus effects of imipramine. Pharmacology, Biochemistry, and Behavior 38, 407-410.
4. 1 receptor antagonist. Nature Medicine 8, 825-830.
5. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002). Induction of locomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agent. Pharmacology, Biochemistry, and Behavior 71, 667-680.
6. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S (2005). The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Current Pharmaceutical Design 11, 1475-1493.
7. 2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). European Journal of Pharmacology 257, 27-38.
8. Clarke RW, Harris J (2002). RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors. CNS Drug Reviews 8, 177-192.
9. 1) receptor antagonist GR205171 on adjuvant-induced inflammatory pain in the rat. British Journal of Pharmacology 122, 27P.
10. 1 adrenergic receptors. Psychopharmacology 154, 70-75.
11. Crissman AM, O'Donnell JM (2002). Effects of antidepressants in rats trained to discriminate centrally administered isoproterenol. Journal of Pharmacology and Experimental Therapeutics 302, 606-611.
12. 2-adrenoceptor agonists, medetomidine, clonidine and UK 14, 304 on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialysis and synaptosomal uptake studies. British Journal of Pharmacology 114, 1717-1723.
13. Davis R, Whittington R, Bryson HM (1997). Nefazodone, a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53, 608-636.
14. 2C agonist. Ro 60-0175: a pharmacological analysis. Neuropharmacology 38, 415-423.
15. Dekeyne A, Gobert A, Iob L, Cistarelli L, Melon C, Millan MJ (2001a). Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats. Psychopharmacology 154, 213-218.
16. 2A antagonist, MDL100,907. Neuropharmacology 44, 604-615.
17. Dekeyne A, Iob L, Millan MJ (2001c). Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology 153, 389-392.
18. Dekeyne A, Millan MJ (2003) Discriminative stimulus properties of antidepressant agents: a review. Behavioural Pharmacology 14, 391-407.
19. Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL (2003). Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacology 167, 79-84.
20. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121, 1-26.
21. Eckler JR, Rabin RA, Winter JC (2003). Nefazodone in the rat: mimicry and antagonism of [-]-DOM-induced stimulus control. Pharmacology, Biochemistry and Behavior 75, 405-410.
22. Eriksson E (2000). Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin? Acta Psychiatrica Scandinavica (Suppl.) 402, 12-17.
23. Filip M, Chojnacka-Wojcik E, Przegalinski E (1993). Discriminative stimulus properties of (+)-oxaprotiline in rats. Polish Journal of Pharmacology 45, 151-156.
24. 1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 26, 1383-1393.
25. 1 antagonist, SNAP7941, enhances cholinergic but not monoaminergic transmission in frontal cortex (FCX) of freely-moving rats. Society for Neuroscience Abstracts 28, P247.8.
26. 2-adrenergic receptor blockade markedly potentiates duloxetine and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. Journal of Neurochemistry 69, 2616-2619.
27. 2C receptor mode of action. Psychopharmacology 137, 292-302.
28. Goudie AJ, Smith JA (1999). Discriminative stimulus properties of antipsychotics. Pharmacology, Biochemistry, and Behavior 64, 193-201.
29. Goudie AJ, Smith JA, Millan MJ (2004). Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology 171, 212-222.
30. Griebel G, Perrault G, Sanger DJ (1998). Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 138, 55-66.
31. Haddjeri N, Blier P, de Montigny C (1998). Acute and longterm actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. Journal of Affective Disorders 51, 255-266.
32. 1A receptors on central noradrenergic activity: microdialysis studies using (+/x)-MDL 73005EF and its enantiomers. Neuropharmacology 38, 299-306.
33. 1- adrenoceptors in the frontal cortex of the rat. Neuropharmacology 31, 955-960.
34. Herpfer I, Lieb K (2005). Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19, 275-293.
35. 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28, 819-827.
36. Isogawa K, Akiyoshi J, Hikichi T, Yamamoto Y, Tsutsumi T, Nagayama H (2000). Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo. Neuropeptides 34, 234-239.
37. Itoh Y, Oishi R, Nishibori M, Saeki K (1990). In vivo measurement of noradrenaline and 3, 4-dihydroxyphenylethyleneglycol in the rat hypothalamus by microdialysis: effects of various drugs affecting noradrenaline metabolism. Journal of Pharmacology and Experimental Therapeutics 255, 1090-1097.
38. 2 adrenoceptors are responsible for a clonidine-induced cue in a rat drug discrimination paradigm. Psychopharmacology 110, 209-212.
39. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty P (1994). In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18, 294-297.
40. Kelley JL, Musso DL, Boswell GE, Soroko FE, Cooper BR (1996). (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake. Journal of Medicinal Chemistry 39, 347-349.
41. Kelley BM, Porter JH, Varvel SA (1995). Mianserin as a discriminative stimulus in rats: asymmetrical cross-generalization with scopolamine. Psychopharmacology 120, 491-493.
42. 2C receptor antagonist. Neuropharmacology 36, 609-620.
43. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP (2003). Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45, 935-944.
44. 1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study. Brain Research 935, 134-139.
45. 1 antagonist, DMP695, abolishes activation of locus coeruleus (LC) noradrenergic perikarya by CRF in anesthetized rats. European Journal of Pharmacology 464, 127-133.
46. 1 antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats. Psychopharmacology 166, 408-415.
47. 1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels. Neuropharmacology 48, 927-935.
48. 2 adrenergic agonist clenbuterol. Pharmacology, Biochemistry, and Behavior 63, 319-324.
49. Marona-Lewicka D, Nichols DE (1998). Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology 138, 67-75.
50. Melia KF, Spealman RD (1991). Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. Journal of Pharmacology and Experimental Therapeutics 258, 626-632.
51. Millan MJ (2003). The neurobiology and control of anxious states. Progress in Neurobiology 70, 83-244.
52. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Thérapie 60, 441-460.
53. Millan MJ (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology & Therapeutics 110, 135-370.
54. 1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25, 585-600.
55. Millan MJ, Dekeyne A, Papp M, Drieu La Rochelle C, MacSweeny C, Peglion J-L, Brocco M (2001b). S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioural profile in comparison to venlafaxine, reboxetine, citalopram and clomipramine. Journal of Pharmacology and Experimental Therapeutics 298, 581-591.
56. 2C are involved in the discriminative stimulus effects of citalopram in rats. Psychopharmacology 142, 432-434.
57. Millan MJ, Gobert A, Girardon S, Dekeyne A (1999b). Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline. European Journal of Pharmacology 364, 147-150.
58. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet J-M, Auclair A, Peglion J-L (2001c). S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological and neurochemical profile in comparison to venlafaxine, reboxetine, citalopram and clomipramine. Journal of Pharmacology and Experimental Therapeutics 298, 565-580.
59. 2C receptors: a comparison with citalopram. European Journal of Neuroscience 12, 1-17.
60. Millan MJ, Lejeune F, De Nanteuil G, Gobert A (2001d). Selective blockade of NK1 receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. Journal of Neurochemistry 76, 1949-1954.
61. Millan MJ, Lejeune F, Gobert A (2000b). Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. Journal of Psychopharmacology 14, 114-138.
62. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. Journal of Pharmacology and Experimental Therapeutics 295, 1206-1222.
63. Morilak DA, Frazer A (2004). Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. International Journal of Neuropsychopharmacology 7, 193-218.
64. O'Donnell JM (1997). Pharmacological characterization of the discriminative stimulus effects of clenbuterol in rats. Pharmacology, Biochemistry, and Behavior 58, 813-818.
65. Okada F, Tokumitsu Y (1994). Is the β-AR down-regulation a prerequisite of the antidepressant activity? Journal of Psychopharmacology 8, 62-63.
66. Pazzagli M, Giovannini MG, Pepeu G (1999). Trazodone increases extracellular serotonin levels in the frontal cortex of rats. European Journal of Pharmacology 383, 249-257.
67. Pei Q, Sprakes M, Millan MJ, Rochat C, Sharp T (2004). The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex. European Journal of Pharmacology 495, 227-233.
68. Pertovaara A, Haapalinna A, Sirvio J, Virtanen R (2005). Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Reviews 11, 273-288.
69. Riva M, Brunello N, Rovescalli AC, Galimbert R, Carfagna N, Carmineti P, Pozzi O, Ricciardi S, Roncucci R, Rossi A, Racagni G (1999). Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. Journal of Drug Development 1, 243-253.
70. 1-adrenergic system. Neuropharmacology 41, 360-368.
71. Roy M, David NK, Danao JV, Baribault H, Tian H, Giorgetti M (2006). Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects. Neuropsychopharmacology 31, 112-120.
72. 1) receptors by GR205171, RP67580, SR140333 and NKP-608. Neuropharmacology 45, 231-241.
73. 1) receptor in assays for antidepressant and anxiolytic drugs. Behavioural Pharmacology 12, 497-508.
74. Sacchetti G, Bernini M, Bianchetti A, Parini S, Invernizzi RW, Samanin R (1999). Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. British Journal of Pharmacology 128, 1332-1338.
75. Sanchez C, Hyttel J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cellular and Molecular Neurobiology 19, 467-489.
76. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, et al. (1996). CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proceedings of the National Academy of Sciences USA 93, 10477-10482.
77. Snoddy AM, Tessel RE (1985). Prazosin: effect on psychomotor-stimulant cues and locomotor activity in mice. European Journal of Pharmacology 116, 221-228.
78. Stahl SM, Grady MM, Moret C, Briley M (2005). SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressant. CNS Spectrums 10, 732-747.
79. Steckler T, Holsboer F (1999). Corticotopin-releasing hormone receptor subtypes and emotion. Biological Psychiatry 46, 1480-1508.
80. 1-adrenergic neurotransmission in necessary for behavioral activation to environmental change in mice. Neuroscience 94, 1245-1252.
81. Szegedi A, Schwertferger N (2005). Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opinion on Pharmacotherapy 6, 631-641.
82. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology 340, 249-258.
83. Terry P, Katz JL (1997). Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology 134, 201-212.
84. Valentini V, Frau R, Di Chiara G (2004). Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. Journal of Neurochemistry 88, 917-927.
85. Versiani M, Amin M, Chouinard G (2000). Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. Clinical Psychopharmacology 20, 28-34.
86. Wahlbeck K, Cheine M, Essali A, Adams C (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry 156, 990-999.
87. Wol. MC, Leander JD (1999). The discriminative stimulus properties of LY233708, a selective serotonin reuptake inhibitor, in the pigeon. Psychopharmacology 146, 275-279.
88. Wong EHF, Sonders MS, Amara SG, Tinholt PM, Piercey MFP, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignon A, et al. (2000). Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biological Psychiatry 47, 818-829.
89. 1 receptors. Journal of Pharmacology and Experimental Therapeutics 305, 57-69.